Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) generates frequent news as a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News coverage of Armata often centers on its lead intravenous phage cocktail AP-SA02 for complicated Staphylococcus aureus bacteremia and its multi-phage candidate AP-PA02 targeting Pseudomonas aeruginosa in chronic respiratory disease.
Readers following ARMP news can expect detailed updates on clinical trial milestones, including topline data, late-breaking conference presentations, and regulatory interactions. Recent announcements have described positive Phase 1b/2a results from the diSArm study of AP-SA02, higher and earlier cure rates compared with antibiotics alone, and an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement of AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia.
Armata’s news flow also includes information on manufacturing and infrastructure, such as the formal commissioning of its cGMP phage manufacturing facility in Los Angeles, California, which is intended to support late-stage clinical development and potential commercial production. Financial and corporate updates appear in quarterly results releases, describing grant and award revenue from the U.S. Department of Defense, secured credit agreements with Innoviva Strategic Opportunities LLC, and at-the-market equity offering arrangements.
Additional coverage highlights scientific publications and conference participation, including structural biology work on phage Pa223 in the Journal of Molecular Biology and presentations at IDWeek, the Military Health System Research Symposium, and the Evergreen Phage Meeting. For investors, clinicians, and researchers, this news page offers a centralized view of Armata’s progress in phage therapy, regulatory dialogue, funding developments, and manufacturing readiness. Bookmark this page to review ongoing ARMP press releases, SEC-linked disclosures, and other company communications as they are released.
Armata Pharmaceuticals (NYSE American: ARMP) has announced a new lease for a 56,300 square-foot research and development and GMP manufacturing facility in Los Angeles. This state-of-the-art facility aims to enhance Armata's phage therapy pipeline and manufacturing capacity, supporting upcoming pivotal studies and commercial launches. The company is advancing its clinical candidates, AP-PA02 and AP-SA02, and believes the facility will facilitate potential strategic partnerships to bolster its pipeline and accelerate development.
Armata Pharmaceuticals (NYSE American: ARMP) announced receiving a $3.0 million equity investment from the Cystic Fibrosis Foundation, with an additional $4.0 million from Innoviva, a significant shareholder. This investment will support Armata's lead clinical candidate, AP-PA02, currently in a Phase 1b/2a trial for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. This follows a prior $5.0 million Therapeutics Development Award from the Foundation in March 2020, emphasizing the urgent need for new therapies against difficult bacterial infections.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13. Armata focuses on developing bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Their pipeline includes candidates for pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, and they collaborate with Merck on synthetic phage candidates targeting an undisclosed infectious disease.
Armata Pharmaceuticals (ARMP) reported its second-quarter 2021 results, noting the retirement of CEO Todd R. Patrick and the appointment of Brian Varnum as his successor. The company received a $750,000 milestone payment from the Cystic Fibrosis Foundation to support its Phase 1b/2a clinical trial for AP-PA02 targeting chronic Pseudomonas aeruginosa infections. Grant revenue was $1.2 million, a significant increase from $31,000 in Q2 2020. However, R&D expenses surged to $5.2 million, contributing to an operating loss of $6.2 million. Armata has $17.5 million in cash as of June 30, 2021.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced on August 2, 2021, that CEO Todd R. Patrick is retiring from day-to-day management, transitioning to the Board of Directors as a special advisor. President Brian Varnum, Ph.D., has been appointed CEO. Patrick highlighted the company's significant progress, including the merger with AmpliPhi Biosciences and clinical trials for AP-PA02. The Board expressed gratitude for Patrick's leadership and confidence in Varnum's drug development experience as the company advances phage-based therapeutics targeting antibiotic-resistant infections.
Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology firm focused on bacteriophage therapeutics for antibiotic-resistant infections, will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 4:00 PM ET. The event will feature one-on-one investor meetings and further details about Armata's innovative pipeline targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Interested parties can access the presentation through a provided webcast link.
Armata Pharmaceuticals, Inc. (ARMP) reported first quarter 2021 results, highlighting progress in clinical trials and financial developments. The company is advancing its SWARM-P.a. Phase 1b/2a trial for treating cystic fibrosis and preparing for a Phase 1b/2 trial for Staphylococcus aureus bacteremia. Armata raised $20 million in gross proceeds from Innoviva, enhancing its financial position, which now includes $22.5 million in cash. The company recognized $1.1 million in grant revenue and expects to achieve several milestones in 2021 and 2022.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced its Q4 and full-year 2020 results, signaling progress in its clinical programs. The FDA cleared the IND application for its lead candidate AP-PA02, aimed at treating Pseudomonas aeruginosa infections. The company appointed Robin C. Kramer to its Board and Mina Pastagia as VP of Clinical Development. Financially, Armata reported Q4 revenues of $0.5 million and a loss from operations of $6.5 million. After raising $20 million from Innoviva, the company has approximately $9.7 million in cash, sufficient to fund operations into Q1 2022.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has successfully closed the second and final tranche of a $20 million private placement with Innoviva, Inc. (NASDAQ: INVA). This transaction raised approximately $13.9 million through the issuance of 4,285,935 common shares and warrants at $3.25 each, following a notable 99% shareholder approval. The first tranche, completed on January 26, 2021, raised $6.1 million. Following both closings, Armata now has 24,940,442 shares outstanding and warrants for 16,649,465 additional shares.
Armata Pharmaceuticals (NYSE American: ARMP) announces participation in the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. Management will present on March 17 at 3:10pm ET. The company focuses on bacteriophage therapeutics targeting antibiotic-resistant bacterial infections, with a diverse pipeline including candidates for Pseudomonas aeruginosa and Staphylococcus aureus. Armata collaborates with Merck to develop synthetic phage candidates for an undisclosed infectious disease.